Obstructive Sleep Apnea and the Liver

Parikh, Malav P.; Gupta, Neena; McCullough, Arthur J.

doi:10.1016/j.cld.2019.01.001

Cited by 34 publications

(30 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Distinct clinical studies have reported that OSA is significantly associated with NAFLD severity ( 26 ) and there is an increasing experimental evidence that chronic IH, the best characterized OSA manifestation, is a major trigger for oxidative stress and inflammatory liver injury leading to NAFLD progression ( 17 ). In agreement with these previous studies, we found that 22.2% of OSA patients had NASH whereas none of those without OSA had histological features of NASH, supporting the assumption that OSA is a risk factor for progression from simple steatosis to NASH ( 27 ).…”

Section: Discussionmentioning

confidence: 99%

Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea

et al. 2020

View full text Add to dashboard Cite

Nocturnal intermittent hypoxia (IH) featuring obstructive sleep apnea (OSA) dysregulates hepatic lipid metabolism and might contribute to the development of non-alcoholic fatty liver disease (NAFLD) observed in OSA patients. However, further research is required to better understanding the molecular mechanisms underlying IH-induced hepatic lipid accumulation. Therefore, the aim of the present study was to determine the effects of OSA on hepatic CD36 expression and the impact of IH by using a mouse model of OSA. Histological analysis, lipid content and CD36 expression were assessed in livers from subjects who underwent liver biopsy and polygraphic study during sleep, and in livers from mice submitted to chronic IH mimicking OSA. Among those who presented OSA features, NAFLD were significantly more frequent than in control subjects with normal respiratory function (77.8 vs. 36.4%, respectively), and showed more severe liver disease. Interestingly, CD36 expression was significantly overexpressed within the liver of OSA patients with respect to controls, and a significant positive correlation was observed between hepatic levels of CD36 and the values of two well-known respiratory parameters that characterized OSA: apnea/hypopnea index (AHI) and oxygen desaturation index (ODI). Moreover, hepatic lipid accumulation as well as induction of hepatic lipogenic genes, and CD36 mRNA and protein expression were significantly higher in livers from mice exposed to IH conditions for 8 weeks than in their corresponding littermates. This study provides novel evidence that IH featuring OSA could contribute to NAFLD setup partly by upregulating hepatic CD36 expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Finally, to which extent sleep apnea and chronic intermittent hypoxia, which are known to result in cognitive impairment [26] and also to be associated with the metabolic syndrome and NAFLD/NASH [27], contributes to the cognitive impairment found in NAFLD still remains to be elucidated.…”

Section: Cognitive Impairmentmentioning

confidence: 99%

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH

2020

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) and its complication non-alcoholic steatohepatitis (NASH) are important causes of liver disease worldwide. Recently, a significant association between these hepatic diseases and different central nervous system (CNS) disorders has been observed in an increasing number of patients. NAFLD-related CNS dysfunctions include cognitive impairment, hippocampal-dependent memory impairment, and mood imbalances (in particular, depression and anxiety). This review aims at summarizing the main correlations observed between NAFLD development and these CNS dysfunctions, focusing on the studies investigating the mechanism(s) involved in this association. Growing evidences point at cerebrovascular alteration, neuroinflammation, and brain insulin resistance as NAFLD/NASH-related CNS manifestations. Since the pharmacological options available for the management of these conditions are still limited, further studies are needed to unravel the mechanism(s) of NAFLD/NASH and their central manifestations and identify effective pharmacological targets.

show abstract

“…109 The data regarding the effect of treatment of OSA with continuous positive airway pressure therapy on NAFLD is divergent; although randomized controlled trials of continuous positive airway pressure did not suggest improvement in NAFLD, observational studies of longer duration did show a beneficial effect. 110,111 Larger, long-term prospective trials are desirable, particularly in pediatrics.…”

Section: Sleep and Hypoxiamentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges

Goldner

Lavine

2020

Gastroenterology

View full text Add to dashboard Cite

Obstructive Sleep Apnea and the Liver

Cited by 34 publications

References 105 publications

Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea

Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH

Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges

Contact Info

Product

Resources

About